论文部分内容阅读
血小板活化、聚集是诱导血管内血栓形成的重要因素,因此,抗血小板治疗在心脑血管疾病的防治中至关重要。然而,现有抗血小板药物虽能降低血栓事件发生,但由于存在抵抗或低应答,不良缺血事件仍有发生;且这些药物产生的消化道大出血、脑出血等并发症严重影响治疗及预后。因此,血小板功能研究及新型抗血小板药物研发仍尤为重要。目前研究发现,多种生物活性肽存在抗血小板活化、聚集等作用。本综述旨在探讨血小板相关活性肽的研究进展。
Platelet activation, aggregation is an important factor inducing intravascular thrombosis, therefore, antiplatelet therapy in the prevention and treatment of cardiovascular and cerebrovascular diseases is essential. However, although the existing anti-platelet drugs can reduce the incidence of thrombosis, adverse ischemic events still occur due to the existence of resistance or low response; and complications such as gastrointestinal bleeding and cerebral hemorrhage caused by these drugs seriously affect the treatment and prognosis. Therefore, the study of platelet function and the development of new anti-platelet drugs are still especially important. The current study found that there are a variety of bioactive peptides anti-platelet activation, aggregation and so on. This review aims to explore the research progress of platelet-associated active peptides.